Search results
Results from the WOW.Com Content Network
Long-term use of ADHD medications can raise the risk of cardiovascular disease in both children and adults, according to a study published Wednesday in JAMA Psychiatry. Experts say that the ...
Zebeta 5-mg oral tablet. Bisoprolol is used for prevention of cardiovascular events following a heart attack in patients with risk factors for disease progression, [16] in the management of congestive heart failure with reduced ejection fraction, [17] and as a second-line agent for hypertension.
Attention deficit hyperactivity disorder management options are evidence-based practices with established treatment efficacy for ADHD.Approaches that have been evaluated in the management of ADHD symptoms include FDA-approved pharmacologic treatment and other pharmaceutical agents, psychological or behavioral approaches, combined pharmacological and behavioral approaches, cognitive training ...
Serious side effects may include angioedema, liver problems, stroke, psychosis, heart problems, suicide, and aggression. [ 13 ] [ 26 ] A 2020 meta-analysis found that atomoxetine was associated with anorexia , weight loss , and hypertension , rating it as a "potentially least preferred agent based on safety" for treating ADHD.
Medications are the most effective treatment, [8] [237] and any side effects are typically mild and easy to resolve [8] although any improvements will be reverted if medication is ceased. [238] ADHD stimulants also improve persistence and task performance in children with ADHD.
A 2018 Cochrane review found that methylphenidate might be associated with serious side effects such as heart problems, psychosis, and death. The certainty of the evidence was stated as very low. [98] The same review found tentative evidence that it may cause both serious and non-serious adverse effects in children. [98] [d]
ADHD medication tied to 19% lower death risk. An observational study conducted in Sweden, whose results appeared in JAMA in March 2024, further emphasized the positive impact of ADHD medication on ...
In 2010, guanfacine was approved by the FDA for the treatment of attention deficit hyperactivity disorder for people 6 to 17 years old. [16] It was approved for ADHD by the European Medicines Agency under the name Intuniv in 2015. [61] It was added to the Australian Pharmaceutical Benefits Scheme for the treatment of ADHD in 2018. [62]